PMID- 17683175
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 67
IP  - 12
DP  - 2007
TI  - Bevacizumab: in first-line treatment of metastatic breast cancer.
PG  - 1793-9
AB  - Bevacizumab, a recombinant humanised monoclonal antibody against vascular 
      endothelial growth factor, is approved in Europe as first-line therapy for 
      metastatic breast cancer (mBC) and metastatic carcinoma of the colon or rectum 
      (mCRC); the European Medicines Agency gave a positive opinion recommending its 
      use in non-small-cell lung cancer (NSCLC) and is also considering other 
      indications. In the US, it is licensed for use for mCRC and NSCLC, with its use 
      as first-line treatment in mBC under review by the US FDA. In the pivotal E2100 
      trial in >700 previously untreated patients with locally recurrent or mBC, 
      recipients of bevacizumab plus paclitaxel had a statistically and clinically 
      significant increase in progression-free survival versus paclitaxel recipients 
      (13.3 vs 6.7 months; hazard ratio 0.48; p < 0.001) [primary endpoint]. There was 
      also a >2-fold higher objective response rate in the bevacizumab plus paclitaxel 
      arm than in the paclitaxel arm; the between-group difference in median overall 
      survival did not reach statistical significance (25.7 vs 23.8 months). 
      Bevacizumab had an acceptable tolerability profile in these patients, with the 
      majority of adverse events being generally mild to moderate in severity. There 
      are targeted adverse events, including gastrointestinal perforations, wound 
      healing complications and haemorrhage, which although they occur infrequently 
      (incidence <=2%), are potentially life-threatening and may cause morbidity.
FAU - Scott, Lesley J
AU  - Scott LJ
AD  - Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of 
      Wolters Kluwer Health, Conshohocken, Pennsylvania, USA. demail@adis.co.nz
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse 
      effects/pharmacokinetics/pharmacology/*therapeutic use
MH  - Animals
MH  - Antibodies, Monoclonal/adverse effects/pharmacokinetics/pharmacology/*therapeutic 
      use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Breast Neoplasms/*drug therapy
MH  - Humans
RF  - 26
EDAT- 2007/08/09 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/08/09 09:00
PHST- 2007/08/09 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/08/09 09:00 [entrez]
AID - 67129 [pii]
AID - 10.2165/00003495-200767120-00009 [doi]
PST - ppublish
SO  - Drugs. 2007;67(12):1793-9. doi: 10.2165/00003495-200767120-00009.